Current oncological medications have been associated with a number of serious cardiac complications. Despite a number of guidelines being available for the diagnosis and treatment of cardiological complications among adult cancer patients, there is still a lack of comprehensive guidelines for managing cardiovascular complications in pediatric patients. To address this gap, a multidisciplinary panel of specialists from Australia and New Zealand has published a set of recommendations for the care of cardiac health in children with cancer.
As part of a series of articles on these guidelines, the following article will focus on the surveillance and management of toxicity associated with Bruton’s Tyrosine Kinase (BTK) inhibitors, immune checkpoint inhibitors, and management of prolonged QT intervals. Recommendations: The introduction of cardio-oncology as a subspecialty has helped…
